Methods and uses of quinoline derivatives in the treatment of soft tissue sarcomas and pharmaceutical compositions for treatment of same
The present invention addresses methods and uses of quinoline derivatives in the treatment of tumors and pharmaceutical compositions for treatment of same. Specifically, the present invention involves a method and applications for the use of the quinoline derivative 1-[[[4-(4-fluoro-2-methyl-H-indol-5-yl)oxy-6-methoxyquinolin-7-yl]oxy]methyl]cyclopropylamine in the treatment of soft tissue sarcomas and pharmaceutical compositions for treatment of same.
1. A method for treating a soft tissue sarcoma, the method comprising administrating Compound I or a pharmaceutically acceptable salt thereof to a patient in need of treatment, wherein the soft tissue sarcoma is selected from malignant fibrous histiocytoma, fibrosarcoma, liposarcoma, leiomyosarcoma, rhabdomyosarcoma, synovial sarcoma, dermatofibrosarcoma protuberans, malignant peripheral nerve sheath tumor, alveolar soft part sarcoma, clear cell sarcoma, hemangiosarcoma, malignant mesenchymoma, epithelioid sarcoma and undifferentiated sarcoma,
2. The method according to claim 1 , wherein the soft tissue sarcoma is an advanced soft tissue sarcoma.
3. The method according to claim 1 , wherein the pharmaceutically acceptable salt comprises a hydrochloride of Compound I.
4. The method according to claim 1 , wherein the daily dosage of the Compound I or the pharmaceutically acceptable salt thereof is 2 mg-20 mg.
5. The method according to claim 1 , wherein Compound I or the pharmaceutically acceptable salt thereof is administrated by an interval administration, and the interval administration includes administration periods and rest periods, wherein the ratio of the administration periods to the rest periods in days is 2:0.5-5.
6. The method according to claim 1 , wherein the soft tissue sarcoma is selected from leiomyosarcoma, synovial sarcoma and alveolar soft part sarcoma.
7. The method according to claim 6 , wherein the soft tissue sarcoma is an advanced soft tissue sarcoma.
8. The method according to claim 6 , wherein the soft tissue sarcoma is an advanced soft tissue sarcoma which has been treated with chemotherapy.
9. The method according to claim 6 , wherein the pharmaceutically acceptable salt comprises a hydrochloride of Compound I.
10. The method according to claim 6 , wherein the pharmaceutically acceptable salt comprises a dihydrochloride of Compound I.
11. The method according to claim 6 , wherein the daily dosage of the Compound I or the pharmaceutically acceptable salt thereof is 2 mg-20 mg.
12. The method according to claim 6 , wherein Compound I or the pharmaceutically acceptable salt thereof is administrated by an interval administration, and the interval administration includes administration periods and rest periods, wherein the ratio of the administration periods to the rest periods in days is 2:0.5-5.
13. The method according to claim 1 , wherein the soft tissue sarcoma is an advanced soft tissue sarcoma which has been treated with chemotherapy.
14. A method of treating a soft tissue sarcoma, the method comprising administering to a patient in need thereof a pharmaceutical composition comprising a therapeutically effective amount of Compound I or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, wherein the soft tissue sarcoma is selected from leiomyosarcoma, synovial sarcoma and alveolar soft part sarcoma,
15. The method according to claim 14 , wherein the soft tissue sarcoma is an advanced soft tissue sarcoma that has been treated with chemotherapy.
16. The method according to claim 14 , wherein the pharmaceutically acceptable salt comprises a hydrochloride of Compound I.
17. The method according to claim 14 , wherein the pharmaceutical composition is a single dosage comprising 2 mg to 20 mg of Compound I or a pharmaceutically acceptable salt thereof.
18. The method according to claim 14 , wherein the composition is administrated by an interval administration, and the interval administration includes administration periods and rest periods, wherein the ratio of the administration periods to the rest periods in days is 2:0.5-5.
19. The method according to claim 1 , wherein the soft tissue sarcoma is selected from malignant fibrous histiocytoma, fibrosarcoma, liposarcoma, leiomyosarcoma, synovial sarcoma, alveolar soft part sarcoma, clear cell sarcoma, and epithelioid sarcoma.
20. The method according to claim 14 , wherein the composition is administrated continuously for 2 weeks and withdrawn for 1 week.